Form 4: INSMED CEO Lewis Exercises Options, Sells Shares

INSMED Inc. Chair and CEO William Lewis exercised stock options and subsequently sold a portion of his common stock holdings on January 12, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• William Lewis, the Chair and CEO of INSMED Inc., reported transactions involving the company's common stock on January 12, 2026.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025.
• Lewis exercised stock options to acquire a total of 10,699 shares of common stock: 6,259 shares at an exercise price of $30.46 and 4,440 shares at an exercise price of $17.16.
• Following the option exercises, Lewis sold a total of 19,215 shares of common stock in multiple transactions at weighted average prices ranging from $167.73 to $174.86 per share.
• After these transactions, Lewis directly beneficially owns 306,891 shares of common stock.
• Additionally, Lewis indirectly beneficially owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, but mitigated by the fact that the transactions were pre-scheduled under a 10b5-1 plan, which reduces the implication of immediate market timing based on non-public information. The executive is monetizing vested options, which is a common practice.

Positives

• The executive exercised stock options at significantly lower prices ($30.46 and $17.16) compared to the sale prices (ranging from $167.73 to $174.86), indicating a profitable monetization of vested equity.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were scheduled in advance and not based on immediate, non-public information.

Negatives

• The CEO sold a substantial number of shares (19,215 shares), which represents a reduction in his direct beneficial ownership, potentially signaling a lack of conviction or a desire to diversify personal holdings.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a negative signal, potentially leading to downward pressure on the stock price if investors interpret it as a lack of confidence from management.

Future Outlook

The filing does not contain forward-looking statements regarding the company's future performance or strategic direction, focusing solely on the insider's trading activities under a pre-arranged plan.

Industry Context

This Form 4 filing reports routine insider trading activity and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.

Related Party Transactions

• William Lewis indirectly beneficially owns shares through the Katie Procter Dynasty Trust (233,924 shares) and the William Lewis Family Legacy Trust (50,500 shares).

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, potentially influencing short-term trading sentiment, although the 10b5-1 plan context typically lessens the negative impact.
• The transactions represent a personal financial event for the CEO and do not directly impact employees, customers, suppliers, or creditors in the immediate term.

Key Dates

Keywords

INSMED Inc., INSM, William Lewis, CEO, Director, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Beneficial Ownership